



Review

Regulation of TEAD Transcription Factors in Cancer Biology

Hyunbin D. Huh ¹, Dong Hyeon Kim ¹, Han-Sol Jeong ²,* o and Hyun Woo Park ¹,*

- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea; huhhb621@yonsei.ac.kr (H.D.H.); dhk1107@yonsei.ac.kr (D.H.K.)
- Division of Applied Medicine, School of Korean Medicine, Pusan National University, Yangsan, Gyeongnam 50612, Korea
- * Correspondence: jhsol33@pusan.ac.kr (H.-S.J.); hwp003@yonsei.ac.kr (H.W.P.); Tel.: +82-51-510-8461 (H.-S.J.); +82-2-2123-2698 (H.W.P.)

Received: 20 April 2019; Accepted: 11 June 2019; Published: 17 June 2019



Abstract: Transcriptional enhanced associate domain (TEAD) transcription factors play important roles during development, cell proliferation, regeneration, and tissue homeostasis. TEAD integrates with and coordinates various signal transduction pathways including Hippo, Wnt, transforming growth factor beta (TGF\u00e4), and epidermal growth factor receptor (EGFR) pathways. TEAD deregulation affects well-established cancer genes such as KRAS, BRAF, LKB1, NF2, and MYC, and its transcriptional output plays an important role in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance. To date, TEADs have been recognized to be key transcription factors of the Hippo pathway. Therefore, most studies are focused on the Hippo kinases and YAP/TAZ, whereas the Hippo-dependent and Hippo-independent regulators and regulations governing TEAD only emerged recently. Deregulation of the TEAD transcriptional output plays important roles in tumor progression and serves as a prognostic biomarker due to high correlation with clinicopathological parameters in human malignancies. In addition, discovering the molecular mechanisms of TEAD, such as post-translational modifications and nucleocytoplasmic shuttling, represents an important means of modulating TEAD transcriptional activity. Collectively, this review highlights the role of TEAD in multistep-tumorigenesis by interacting with upstream oncogenic signaling pathways and controlling downstream target genes, which provides unprecedented insight and rationale into developing TEAD-targeted anticancer therapeutics.

Keywords: TEAD; Hippo pathway; cancer; stem cell

1. Introduction

The TEAD family of transcription factors are the final nuclear effectors of the Hippo pathway, which regulate cell growth, proliferation, and tissue homeostasis via their transcriptional target genes. Since their initial discovery three decades ago, TEADs have been best studied in the context of the Hippo-YAP/TAZ signaling pathway and tumorigenesis. To date, studies on TEAD activity are limited to serving as the functional readout of the Hippo-YAP/TAZ pathway. However, recent evidence suggests that nucleocytoplasmic shuttling, post-translational modifications, and crosstalk between oncogenic signaling pathways are important determinants of TEAD activity both in vitro and in vivo. Importantly, since the Hippo pathway components are hardly druggable, TEADs have emerged as critical drug candidates to treat human diseases including cancer, cardiovascular diseases, and neurodegenerative disorders. The current review underscores and reinterprets the oncogenic role of TEADs in tumorigenesis in past reports from a TEAD point of view in order to provide unprecedented insight and rationale into developing TEAD-targeted anticancer therapeutics.

2. The TEAD Family of Transcription Factors

All four TEADs are transcription factors that are evolutionarily conserved and broadly expressed in most tissues of the human body [1,2]. Each family member has multiple names TEAD1 (TEF-1/NTEF), TEAD2 (TEF-4/ETF), TEAD3 (TEF-5/ETFR-1), and TEAD4 (TEF-3/ETFR-2/FR-19). Despite the high homology and expression pattern shared between TEAD1-4, animal model experiments indicate that each TEAD has tissue-specific roles, such as cardiogenesis, neural development, and trophectoderm lineage determination, during embryonic development [3–8]. One of their major roles in cell biology is to regulate cell proliferation and contact inhibition [9,10]. TEADs also share highly similar domain architectures (Figure 1). TEAD N-terminus share a highly conserved 68-amino acid TEA/ATTS DNA-binding domain, which binds to the MCAT element (5'-CATTCCA/T-3') originally defined as the GT-IIC motif (5'-ACATTCCAC-3') of the simian virus 40 (SV40) enhancer [11-13]. Based on these sequences, a synthetic TEAD luciferase reporter 8xGTIIC-luciferase plasmid, which contains eight GT-IIC motifs, is being widely used to measure YAP/TAZ and TEAD activity [14]. Unlike several other transcription factors, TEAD is known to be mostly bound to the DNA since the majority of TEADs are found in the chromatin fraction [15]. However, they hardly exhibit any transcriptional activity by themselves [16]. Hence, TEAD activity mainly relies on the C-terminus, in which all TEADs share their transactivation domain in order to recruit transcriptional coactivators YAP/TAZ [17-20], corepressors VGLL1-4 [21–26], chromatin remodeling factors NuRD [27], and the Mediator [28]. Although TEAD has been recognized as the final effector of the Hippo-YAP/TAZ pathway, TEAD also interacts with other signaling transduction pathway transcription factors including TCF, SMAD, OCT4, AP-1, and MRTF [29–33] (Figure 2a). TEAD-driven transcriptional targets include well-established genes that are involved in cell growth, proliferation, and tissue homeostasis. In addition to classical TEAD target genes such as CTGF and CYR61 [18], recent studies also identify WNT5A/B [34], DKK1 [34,35], TGFB2 [36], BMP4 [37], AREG [38], EGFR [39], PD-L1 [40-43], MYC [44,45], LATS2 [46], amino acid transporters SLC38A1/SLC7A5 [47,48], and glucose transporter GLUT3 [49] as direct TEAD target genes (Figure 2a). These signaling inputs, protein-protein interactions, and target genes further expand the roles of TEAD to directly control Wnt, TGFβ, RTK, mTOR, and Hippo signaling in the context of tumorigenesis, cancer immunity, stem cell pluripotency, metabolism, and development.




Figure 1. Domain architecture of human TEADs. The N-terminal DNA binding domain (DNA-BD) and C-terminal YAP/TAZ binding domain (YAP/TAZ-BD) of TEAD1-4 harbor high similarity across four different paralogs. The percent (%) represents the identity for each domain of TEADs compared to that of TEAD1 [50]. TEAD post-translation modifications include palmitoylation and PKA-, PKC-mediated phosphorylation that occur in the YAP/TAZ-BD and DNA-BD, respectively. Palmitoylation is required for proper TEAD functions. TEAD cytoplasmic translocation occurs through protein-protein interaction with p38 MAPK that binds the p38-binding motif within the DNA-BD of all TEADs.




Figure 2. The regulatory mechanisms of TEAD in cancer biology. (a) Upstream signaling and downstream transcriptional outputs of TEAD. Various oncogenic signal transduction pathways, such as EGFR signaling, $TGF\beta$ signaling, Wnt signaling, GPCR signaling, and cancer genes (*), such as KRAS, BRAF, LKB1, APC, GNAQ/11 regulate TEAD activity through multiple signaling mechanisms. The TEAD transcriptional outputs have critical functions in tumorigenesis, stem cell maintenance, cancer immunology, metabolism as well as formation of signaling feedback loops. (b) Role of TEAD in multiple stages of tumorigenesis. TEAD activation via various oncogenic pathways play critical roles in cancer biology including EMT, metastasis, drug resistance, and cancer stem cells.

3. Signaling Inputs and Transcriptional Outputs of TEAD

3.1. Hippo Pathway

Since TEADs exhibit minimal transcriptional activity by themselves, they require coactivators to induce target gene expression [16]. The most well-established cofactors that activate TEAD-mediated transcription are YAP and its paralog TAZ, which are transcriptional coactivators of the Hippo pathway that play major roles in organ size control, cell proliferation, tumorigenesis, and stem

Cells **2019**, *8*, 600 4 of 22

cell self-renewal [51–54] (Figure 2a). The N-terminus of YAP/TAZ interact with the C-terminal transactivation domain of TEAD to form a YAP/TAZ-TEAD complex that constitutes the nuclear transcriptional module of the Hippo pathway [55]. On the other hand, the cytosolic kinase modules of the Hippo pathway, which consists of MST1/2, MAP4K4, and LATS1/2, phosphorylate YAP/TAZ at multiple sites. This promotes YAP/TAZ cytoplasmic retention, ubiquitination, and protein degradation [56]. Cytoplasmic YAP/TAZ are degraded by both the ubiquitin-proteasome system and autophagy [57–60], which renders TEAD transcriptionally inactive.

To date, numerous studies and ChIP-seq analyses highlight YAP/TAZ to be the major TEAD coactivators. In MDA-MB-231 breast cancer cells that harbor genetic inactivation of the Hippo pathway (*NF*2 null), approximately 80% of TEAD4-bound promoters and enhancer regions were co-occupied with YAP/TAZ, while the TEAD consensus sequence was present in 75% of DNA-bound YAP/TAZ peaks [32]. In MCF10A mammary gland epithelial cells, YAP and TEAD1 co-occupied 80% of the promoters [18]. Furthermore, in glioblastoma cells, 86% of all YAP peak regions contained at least one TEAD binding site [61]. Although YAP/TAZ can interact with different transcription factors such as RUNX, p73, KLF4, TBX5, SMAD, and others, TEADs are the predominant factors that facilitate YAP/TAZ recruitment to the chromatin. In mouse studies, dominant-negative TEAD2 was found to be sufficient in suppressing YAP overexpression-, or NF2 inactivating mutation-induced hepatomegaly and tumorigenesis, which indicates that TEAD mostly attributes to YAP-induced tumorigenesis [62]. Although oncogenic driver mutations have not been reported in TEADs, numerous studies demonstrate their pro-tumorigenic roles due to their crosstalk with other cancer genes, which is discussed in later sections.

Furthermore, studies have shown that TEAD interaction is required for YAP/TAZ nuclear retention. Osmotic stress-activated p38 MAPK induces TEAD cytoplasmic translocation independent of the Hippo-YAP/TAZ pathway. In this context, YAP/TAZ fails to accumulate in the nucleus regardless of its phosphorylation status [63]. In TEAD knockout cells, YAP/TAZ remained in the cytoplasm even after treating YAP/TAZ activating stimuli such as LPA and serum [63], and, similarly, TAZ mutants defective in terms of TEAD interaction showed impaired nuclear accumulation [64]. In addition, forced expression of wild-type TEAD2, but not the YAP/TAZ binding deficient-TEAD2 mutant, induced nuclear localization of YAP/TAZ, which was required for tumorigenesis [65]. These results suggest a possible mechanism by which the TEAD interaction is required for YAP/TAZ accumulation and activation in the nucleus.

Moreover, the TEAD transcriptional output also regulates Hippo-YAP/TAZ signaling via target gene expression. TEAD target genes include important membrane transporters and secreted ligands that act through autocrine or paracrine signaling. The *AREG*, *WNT5A/B*, and *TGFB2* ligands activate YAP/TAZ via EGFR [66,67], Frizzled/ROR [34,68,69], and TGFBR [70–72], respectively, while *SLC38A1/SLC7A5* and *GLUT3* activate YAP/TAZ via mTORC1 [58] and glycolytic enzymes [49,73] respectively. Therefore, these TEAD-dependent positive feedback loops function as a nexus that coordinates important biological pathways and deregulation may lead to human malignancies. TEADs also induce *LATS2*, *NF2*, and *AMOTL2*, which are major components of the Hippo pathway, to form a negative feedback loop [46,74]. Thus, these TEAD-mediated feedback loops provide an efficient mechanism by which the robustness and homeostasis of Hippo-YAP/TAZ regulation is established.

3.2. Wnt Pathway

The canonical Wnt/ β -catenin pathway and alternative Wnt pathway are one of the best characterized upstream signal transduction pathways that regulate TEAD. Crosstalk between the Wnt and Hippo pathways converge on TEAD via destruction complex-dependent and -independent mechanisms, which have been studied in the context of tumorigenesis, stem cell biology, and development. In these contexts, TEAD activity is indispensable for Wnt-induced biological responses (Figure 2a).

Cells **2019**, *8*, 600 5 of 22

Canonical Wnt/ β -catenin pathway regulates TEAD and YAP/TAZ via both Hippo-dependent and -independent mechanisms. Using immunoprecipitation assay, YAP/TAZ were shown to directly interact with the β -catenin destruction complex consisting of Axin1, APC, and GSK3 β [75,76]. Within the destruction complex, YAP bridges β -TrCP E3 ligase to degrade β -catenin. Another study shows that APC binds and activates the Hippo pathway components, LATS1 and Sav1, which, in turn, inhibits YAP/TAZ [77]. In both cases, Wnt stimulation or loss-of-function mutations in APC trigger YAP/TAZ nuclear translocation and TEAD-mediated transcription. Furthermore, YAP/TAZ mediates >50% of the Wnt target genes induced by APC deletion in transformed mammary epithelial cells [75]. TEAD4 also directly interacts with TCF4, and the TEAD4-TCF4 complex directly links Wnt/ β -catenin and Hippo/YAP signaling at the transcription factor level [29]. Thus, TEAD transcriptional output underlies the pathogenesis of APC mutation-induced colorectal tumorigenesis and Wnt-induced crypt regeneration.

The alternative Wnt pathway, which is independent of β -catenin and the destruction complex, also plays an important role in tumorigenesis, differentiation, development, and Wnt/ β -catenin signaling inhibition. The alternative Wnt ligand Wnt5A/B is a potent TEAD activator that signal via the Frizzled/ROR1-G $\alpha_{12/13}$ -Rho GTPases-Hippo-YAP/TAZ pathway in the context of cancer progression and mesenchymal stem cell differentiation [34]. Subsequent studies further demonstrate YAP/TAZ and TEAD activation via the alternative Wnt pathway in the context of breast cancer progression, chemotherapy resistance, stem cell maintenance, and macrophage polarization [68,69,78,79].

Moreover, the TEAD transcriptional output regulates the Wnt pathway. Major TEAD target genes that inhibit Wnt/ β -catenin pathway are *DKK1* and *WNT5A/B*. These are well-established secreted inhibitors of the canonical Wnt/ β -catenin pathway [34,35]. Wnt3a stimulation induces *WNT5A/B* gene expression via TEAD, which suppresses Wnt/ β -catenin-induced mesenchymal stem cell differentiation [34]. In addition, YAP represses *WNT3* gene expression to inhibit the Wnt/ β -catenin pathway possibly via TEAD [80]. Although YAP has often been shown to inhibit Wnt-induced biological responses in cancer and stem cells [35,81–83], the precise involvement of the TEAD transcriptional output requires further investigation. Collectively, TEADs are activated via the upstream Wnt pathway, while the TEAD transcriptional output concomitantly inhibits Wnt signaling, thus forming a negative feedback loop.

3.3. TGFβ Pathway

The TGF β pathway regulates multiple biological processes including embryonic development, stem cell differentiation, immune regulation, wound healing, and inflammation. The crosstalk between the TGF β and Hippo pathway centers on Smad and TEAD transcription factors, respectively. TGF β stimulation triggers TEAD-mediated biological responses in the context of cell fate determination, tumorigenesis, and fibrosis, which are either dependent or independent of Smads (Figure 2a). TGF β increases the expression level and activity of TEAD, and vice versa, TEAD can also directly trigger TGF β signaling. TGF β induces TAZ expression via a Smad3-independent, p38-mediated, and MRTF-mediated mechanism [84]. TGF β also induces TEAD2 expression during epithelial-to-mesenchymal transition (EMT) [65]. Thus, TGF β -induced TEAD target gene expression promotes EMT in mammary gland epithelial cells and malignant tumor phenotypes. Notably, the TGFBII ligand itself is a direct target gene of TEAD that evokes a positive feedback regulation [36,85].

Upon TGF β stimulation, Smad2 and Smad3 form complexes with Smad4 and accumulate in the nucleus. It is important to note that TGF β -induced Smad nuclear translocation is dependent on YAP/TAZ. For example, lung and breast cancers lacking RASSF1A display hyperactive TGF β signaling and tumor invasion via the YAP-dependent nuclear localization of Smad2 [70]. In human embryonic stem cells, TAZ is also required for TGF β -induced nuclear translocation of the Smad2/3-4 complex, and TAZ-dependent Smad2/3 nuclear translocation is required to maintain self-renewal markers [71]. YAP/TAZ also regulates the localization of the Smad complex in response to cell

density-mediated formation of polarity complexes [86]. However, the direct involvement of TEAD in YAP/TAZ-dependent Smad localization requires further investigations.

It is still unknown how TGF β signaling switches from enforcing pluripotency to promoting mesendodermal differentiation during development. Smad2/3 forms an enhancer complex with TEADs and OCT4, which suppress the gene expression of differentiation markers and modulates the levels of core pluripotency genes. This maintains the pluripotency of embryonic stem cells [30]. An independent study showed that TEAD binds the negative elongation factor and blocks Wnt3a/ β -catenin and Activin/Smad2/3-induced mesendodermal differentiation [87]. TEAD also mediates TGF β -induced tumorigenesis. The majority of malignant mesotheliomas harbor genetic inactivation of the Hippo pathway components, which collaborate with the TGF β pathway by forming the YAP-TEAD4-Smad3-p300 complex on the CTGF promoter to induce gene expression and tumor growth [88]. Furthermore, a multitude of genes harbor both Smad-binding and TEAD-binding elements in their promoters. In breast cancer cells, TGF β -YAP/TAZ-TEAD signaling is crucial in driving late-stage metastatic phenotypes via Smad2/3-induced *NERG1* and *UCA1* transcription [72]. Accumulating evidence highlights the importance of the TEAD transcriptional output acting as a bona fide effector of the TGF β pathway during development and tumorigenesis.

4. Molecular Mechanisms Controlling TEAD Activity

4.1. Regulation of TEAD via Subcellular Localization

Transcription factors have been shown to form distinct protein complexes both on and off the chromatin [15]. Important signaling pathways function by ultimately regulating the activity and subcellular localization of transcription factors. For example, the final effectors of the $TGF\beta$, Wnt, NFkB, and Hippo signaling pathways are Smads, TCF/LEF, p65, and TEAD transcription factors, respectively, and their chromatin association is tightly controlled via complex upstream signals. Unlike many other transcription factors, a majority of TEAD proteins reside on the chromatin [15], which are known to be passively regulated and dependent on cofactors such as YAP/TAZ and VGLL4. However, mechanistic insight that governs dynamic TEAD subcellular localization was recently elucidated.

There is a wide range of cellular stress, such as energy starvation, oxidative stress, cytotoxic agent, which induce Hippo kinase activation, YAP/TAZ phosphorylation, cytoplasmic translocation, protein degradation, and thus inhibition of TEAD transcriptional outputs. However, these stimuli did not alter TEAD subcellular localization or expression levels. Interestingly, certain environmental stresses, such as osmotic stress, high cell density, and cell suspension, promoted TEAD cytoplasmic translocation [89]. Although controversial, the cytoplasmic localization of TEAD4 has been observed in the inner cell mass of mouse embryonic stem cells [90,91]. Cytoplasmic TEADs were also detected in lung, spleen, and kidney tissues, but not in renal cell carcinoma tissues [63]. A splicing isoform of TEAD4, which lacks the N-terminal DNA binding domain, is found in the cytoplasm acting as a dominant negative isoform that inhibits YAP activity [92]. Because TEADs are the major effectors that dictate the transcriptional output of the Hippo-YAP/TAZ pathway, physiologic and pathologic conditions affecting TEAD localization significantly impact the functional output of the Hippo pathway.

The molecular mechanism of stress-induced cytoplasmic translocation of TEAD involves the p38 MAPK pathway, which is independent of Hippo pathway components [89]. Therefore, the crosstalk between p38 MAPK and the Hippo pathway impinges on TEAD (Figure 2a). The p38-binding motif is located near the N-terminus nuclear localization signal (NLS) of TEADs through which TEAD-p38 forms a complex via direct protein-protein interaction (Figure 1). Although p38 does not phosphorylate TEAD directly, its kinase activity is required for TEAD-p38 complex formation and subsequent cytoplasmic translocation. Cellular responses to environmental stresses are mediated by distinct gene expression during the acute and adaptation phases [93]. During the acute phase of osmotic stress, YAP-TEAD is activated via NLK-mediated YAP S128 phosphorylation [94,95]. However, during the adaptation phase to stress, p38 binds and inhibits TEAD by inducing its cytoplasmic translocation,

Cells **2019**, *8*, 600 7 of 22

which indicates that the TEAD transcriptional output is required for cell survival upon the acute stress response, but is indispensable during the adaptation phase.

More importantly, the nuclear absence of TEAD impairs YAP/TAZ nuclear accumulation [63–65]. For example, in TEAD 1/2/4 KO cells, LPA-stimulated YAP/TAZ fails to accumulate in the nucleus even after it is completely dephosphorylated [63]. Therefore, stimuli that evoke TEAD cytoplasmic translocation overrides YAP/TAZ activating signals. The mechanism of stress- and p38-induced TEAD cytoplasmic retention is intact in various cancer cells. Notably, YAP-driven cancer cells, such as the GNAQ/11 mutant uveal melanoma cells and Hippo mutant mesothelioma cells, were specifically sensitive to TEAD cytoplasmic translocation when compared to YAP-independent cancer cells [63]. These findings suggest that signal transductions and/or chemical compounds that modulate TEAD subcellular localization potentially predominate the biological function of the Hippo-YAP/TAZ pathway.

4.2. Regulation of TEAD via Post-Translational Modifications

The post-translational modifications in TEAD have recently gained significant interest after its important roles in human pathophysiology came to light. To date, TEAD phosphorylation and palmitoylation have been shown to regulate its function. TEAD is phosphorylated by protein kinase A (PKA) and protein kinase C (PKC), which have been shown to inhibit TEAD by disrupting its DNA-binding [96,97] (Figure 1). However, the precise mechanism and context of TEAD phosphorylation requires further investigation. Recently, TEAD palmitoylation emerged as an important post-translational regulation mechanism [98–100]. Protein palmitoylation is important for protein trafficking and membrane localization [101]. S-palmitoylation of TEAD occurs by attaching a fatty acid (palmitate) to conserved cysteine residues in the TEAD C-terminus, which are within the YAP-binding domain (YBD) that share > 70% sequence identity among TEAD1-4 (Figure 1). The palmitoyl group is buried deep inside a hydrophobic pocket of TEAD as revealed by structural studies. All four TEAD paralogs are found palmitoylated in mammalian cells via an autopalmitoylation process that could be removed via a certain depalmitoylating enzyme such as APT2 [99,102]. Although the molecular mechanisms of YAP/TAZ and TEAD regulation via TEAD-YBD palmitoylation have been proposed, the functional role of YBD palmitoylation still remains unclear. Noland et al. and Mesrouze et al. showed that TEAD palmitoylation did not alter protein localization and YAP/TAZ binding. However, it was required for proper TEAD folding and protein stability [99,100]. Impaired TEAD2 palmitoylation decreased TEAD protein stability and resulted in the loss of protein abundance. On the other hand, Chan et al. demonstrated that TEAD palmitoylation did not affect its protein stability. However, it was required for the YAP/TAZ interaction. Palmitoylation-deficient TEAD mutants were not able to bind YAP/TAZ. Therefore, TEAD transcriptional activity was impaired, which indicates that TEAD palmitoylation plays important roles in regulating its binding to the transcriptional coactivators. Palmitoylation-deficient mutants have been reported to be properly folded and could still bind VGLL4, which suggests that the loss of YAP/TAZ binding is not due to TEAD misfolding [98]. The palmitoylation-deficient TEAD1 mutant also impaired TAZ-mediated muscle differentiation and YAP-mediated tissue overgrowth in Drosophila.

Thus, the precise role of TEAD palmitoylation requires in-depth investigation since the palmitate-binding hydrophobic pocket located in the YBD is likely to be an important site for therapeutic intervention. The first indication that the hydrophobic pocket could be a therapeutic target was obtained from a high-throughput screening that attempt to identify ligands that stabilized the TEAD-YBD. The results indicated that NSAIDs, such as flufenamic acid (FA) and niflumic acid (NA), were small-molecular inhibitors that bound the central TEAD hydrophobic pocket at its palmitoylation site [103]. Although the affinity of these drugs to TEAD requires optimization, FA- and NA-treatments decreased TEAD transcriptional activity and TEAD-induced cell migration and proliferation without disrupting TEAD-YAP interaction. Whether FA and NA compete against TEAD palmitoylation requires further investigation.

5. Roles of TEAD in Cancer Biology

5.1. TEAD Expression in Human Cancers

Numerous studies suggest the importance of TEAD in the development of human cancers. TEAD overexpression and hyperactivity has been implicated in multiple stages of cancer progression (Figure 2b). Although TEAD may be downregulated in some breast cancers and renal or bladder tumors [104], high TEAD expression levels have been correlated with poor clinical outcome, which serves as a prognostic marker in various solid tumors, such as prostate cancers [105], colorectal cancers [106,107], gastric cancers [108,109], breast cancers [110,111], germ cell tumors [112,113], head and neck squamous cell carcinomas [114], renal cell carcinomas [115], and medulloblastomas [116]. On the other hand, a loss-of-function mutation in TEAD1 (Y421H) was shown to cause Sveinsson's chorioretinal atrophy, which is a genetic disorder that results in degeneration by disrupting TEAD1-YAP interaction [117,118]. In accordance with these studies, meta-analysis studies revealed that both total and nuclear YAP and TAZ expression are intimately associated with adverse overall survival (OS) and disease-free survival (DFS) in numerous cancers, which suggests the prognostic role of TEADs and YAP/TAZ expression in patients with various malignancies [119,120]. Notably, TEAD was shown to be a critical drug target in YAP-driven tumorigenesis. In hepatocellular carcinoma (HCC), dominant-negative TEAD reversed YAP-induced hepatomegaly and tumorigenesis in vivo. Moreover, VGLL4-mimicking peptide (which binds the YBD) and verteporfin (a small YAP-binding chemical) were demonstrated to harbor therapeutic effects against YAP-induced tumorigenesis by interrupting TEAD-YAP interaction [62,121,122].

5.2. Role of TEAD in EMT

TEADs have emerged as important drivers of cancer development, tumor growth, EMT, metastasis, and drug resistance (Figure 2b). EMT is a natural developmental process that is phenocopied by cancer cells of epithelial origin. This process is crucial for cancer cells since it promotes cell migration, invasion, and anoikis resistance. Therefore, EMT emerged as a critical regulator of the cancer stem cell phenotype and a prerequisite for metastasis [123]. TEADs are critical mediators of EMT and metastasis during cancer progression. Numerous studies indicate that the TEAD transcriptional output induced by YAP/TAZ activation drives cell transformation by inducing EMT [17,18,124–126]. In these studies, TEAD activation disrupted cell-cell junctions, promoted mesenchymal gene expression, and increased cell migration and invasion. Aberrant TEAD activity was shown to promote mammary carcinoma and melanoma metastasis in a manner that was highly dependent on the YAP-interaction domain, which suggests that the interaction between TEAD and YAP is essential for EMT and metastasis [126]. TEAD also contributes to EMT by upregulating Slug and ZEB1 [127,128], which are major EMT transcription factors that promote cell migration and invasion by inhibiting epithelial markers and upregulating mesenchymal markers. TEAD triggers transcriptional induction of ZEB1 that drives metastatic squamous cell carcinoma. ZEB1 and TEAD also forms a complex to promote cancer stem cell traits and predict poor survival, therapy resistance, and increased metastatic risk in breast cancer [129]. In line with ZEB1, TEAD directly transcribes ZEB2 and represses DNp63 to regulate cell fate and lineage conversion in lung cancer progression [130]. Moreover, TEAD mediated non-small-cell lung carcinoma (NSCLC) aggressiveness by inducing Slug transcription and EMT [128]. Collectively, accumulating evidence indicates that TEAD functions as a critical EMT transcription factor in tumorigenesis. It will be interesting to answer key questions regarding the role of TEAD in EMT during development and MET (mesenchymal-to-epithelial transition), which occurs during metastatic colonization.

5.3. Role of TEAD in Metastasis

The majority of cancer-associated deaths occur due to metastasis, which is the dissemination of cancer cells from the primary tumor site to secondary organs. In order to metastasize, cancer cells must avoid anoikis (detachment-induced apoptosis) and must enter and exit from the blood vessels

(intravasation and extravasation, respectively), complete metastatic colonization, and acquire drug resistance. These are all hallmarks of cancer stem cells. Upon interaction with platelets, metastatic cancer cells induce TEAD activation via the RhoA-MYPT1-PP1-YAP pathway. The platelet-activated TEAD transcriptional program in detached cancer cells induced anoikis-resistance and promoted cell survival and metastasis [131]. Similarly, YAP promotes anoikis-resistance upon cell detachment in cancer cells [132]. Cancer cells exposed to shear stress or disturbed flow also activates TEAD via ROCK-LIMK-cofilin signaling, which promotes cancer cell motility and metastasis [133]. Furthermore, the activation of TEAD target gene, CTGF, mediates the metastatic colonization of breast cancer through leukemia inhibitory factor receptor (LIFR) suppression [134]. In colorectal cancer, RARγ promoted TEAD activation through the Hippo pathway, which induces EMT, invasion, and metastasis [135]. However, increased TEAD expression and its nuclear localization in colorectal cancer cells promote EMT and metastasis via a Hippo-independent mechanism [107]. Moreover, TEAD activation induces ROR1-HER3-mediated osteoclast differentiation and bone metastasis of cancer cells via the Hippo-YAP pathway [136]. MRTF-activated TEAD also promotes breast cancer cell metastasis to the lung [33]. In breast cancer and melanoma cells, SRC tyrosine kinase-induced cell-ECM adhesion activates TEAD to promote tumor growth and enhance metastasis [137]. In addition, TGFβ-induced TEAD transcriptional activity is required to promote metastatic phenotypes in breast cancer cells [72]. ARHGAP29 is a TEAD target gene that increases cell invasion and metastasis by regulating actin dynamics in cancer cells [138]. TEADs are also involved in metastatic seeding via disseminated cancer cells. The spreading of circulating tumor cells induced TEAD activation via L1CAM-ILK-YAP signaling, which is critical for metastatic colonization [139]. Collectively, these studies suggest that TEAD activation enhances metastatic tumor formation and raises the possibility that TEAD inhibition can prevent the survival and outgrowth of disseminated tumor cells.

6. TEADs as Mediators of Cancer Genes

Driver mutations in cancer-associated genes alter downstream signaling and transcription patterns, which are critical in tumor progression. Deregulation of TEAD transcriptional output have been demonstrated to mediate the pathology of critical oncogenes and tumor suppressor genes including NF2, BRAF, KRAS, MYC, PTEN, LKB1, and PKA (Figure 2a). This section will discuss the molecular mechanisms of TEAD regulation in the context of cancer gene-induced tumor development, drug resistance, and metastasis.

6.1. Hippo Pathway and TEADs

The Hippo pathway functions as a tumor suppressor pathway, whose activity is deregulated in many cancers [140]. However, mutations directly linked to alterations in the Hippo-YAP/TAZ pathway is uncommon. Inhibition of the core Hippo pathway components via point mutations and epigenetic alterations are found in subsets of human cancers including mutations in NF2 [141–143], MST1/2 [144,145], SAV1 [146], MOB1A/B [147], LATS1 [148–152], and LATS2 [88,153-155]. In addition, approximately 80% of uveal melanomas harbor activating mutations in GNAQ or GNA11, which are associated with the inhibition of the Hippo pathway and activation of TEAD [156,157]. Moreover, gain-of-function mutations were recently found in YAP and TAZ. Hyperactivating mutations in YAP were identified in melanoma and lung cancer patients [158–160]. Furthermore, chromosomal translocations that generated fusion proteins containing YAP (YAP-TFE3) and TAZ (WWTR1-CAMTA1) are oncogenic drivers in epithelioid hemangioendothelioma [161-163]. Similarly, in poromas and poro-carcinomas, fusion proteins containing YAP (YAP-MAML2, YAP-NUTM1) and TAZ (WWTR1-NUTM1) induced tumorigenesis via TEAD hyperactivation [164]. Several studies demonstrated that TEAD hyperactivation drives tumorigenesis driven via Hippo-YAP/TAZ pathway mutations, which suggests TEADs are therapeutic targets [141,143,157,158,162]. However, further investigations are required to link TEAD activity to the pathophysiology of each cancer gene within the Hippo pathway.

6.2. EGFR-RAS-RAF-MAPK Pathway and TEADs

TEADs are mediators of the EGFR-RAS-RAF-MAPK pathway, which is one of the most deregulated molecular pathways in human cancers. TEADs play important roles in tumor progression and drug resistance downstream of the hyperactivating mutations on EGFR, KRAS, or BRAF (Figure 2a). In NSCLC patients, TEAD activity correlates with the EGFR mutation status. EGFR mutant lung cancer tissues and cell lines show upregulated YAP expression, followed by increased TEAD activity [165]. Although EGFR acquires drug resistance to TKI via the T790M mutation, TEAD inhibition effectively reduces the viability of TKI-resistant lung adenocarcinoma cells [166,167]. TEAD also contributes to the immune escape of NSCLC cells by directly transcribing PD-L1, which, in turn, causes CD8⁺ T cell exhaustion [43,168]. Furthermore, TEAD increases EGFR expression by directly binding to the EGFR promotor, which induces tumorigenesis and drug resistance in esophageal cancer [39]. The KRAS oncogene, which is downstream of EGFR, is one of the most frequently mutated proteins in human carcinoma. Activating mutations in KRAS are particularly prominent in pancreatic ductal adenocarcinoma (PDAC). Unlike EGFR and BRAF, KRAS has, thus far, not been considered to be a viable therapeutic target, which renders downstream effectors critical in the treatment of PDAC. Activation of TEAD-induced target genes including COX2 and MMP7, which fueled KRAS^{G12D} driven-PDAC progression both in vivo and in vitro, suggests Celebrex (COX2 inhibitor) and marimastat (a clinical MMP inhibitor) to be possible therapeutic agents for PDAC treatment [169]. Moreover, numerous TEAD target genes have been associated with unfavorable prognosis for PDAC [170]. TEAD2 was shown to act cooperatively with the E2F transcription factor to promote a cell-cycle gene expression program, which enabled the bypass of oncogenic KRAS addiction in PDAC and evoked KRAS-independent tumor relapse [171]. Approximately half of metastatic melanoma patients harbor the BRAF^{V600} mutation, with the most common being BRAF^{V600E} [172]. Although vemurafenib (PLX4032) and dabrafenib were developed to treat BRAF^{V600}-mutant metastatic melanoma, a majority of patients ultimately became resistant [173]. Multiple studies have demonstrated that TEAD activity contributes toward BRAF inhibitor-resistance in melanoma cells. TEAD activity was increased in drug resistant-melanoma cells due to actin cytoskeletal remodeling that induced cancer stemness and invasion [174,175]. BRAF inhibitor-resistant cells can evade the immune system via TEAD activation. TEAD-mediated direct transcription of PD-L1 was responsible for PD-1-dependent CD8⁺ T cell exhaustion, which allowed BRAF inhibitor-resistant cells to escape the immune responses [41,42]. Moreover, TEAD induced cytokines IL-6 and CSF1-3 in KRAS mutant PDAC cells to recruit myeloid-derived suppressor cells (MDSCs), which formed an immunosuppressive tumor microenvironment [176]. Collectively, the TEAD transcriptional output played critical functions in the pathogenesis of the EGFR-RAS-RAF-MAPK pathway and mutation-induced tumor progression.

6.3. LKB1-AMPK Signaling, Energy Stress, and TEADs

LKB1 (STK11) is a well-characterized tumor suppressor that governs diverse cellular processes, including cell growth, polarity, and metabolism. Approximately 15% to 30% of NSCLC patients harbor LKB1 inactivating mutations. An RNAi-based kinome screen identified LKB1-MARK signaling as a potent inhibitor of TEAD transcription activity by inactivating YAP, which suggests TEAD to be a therapeutic target in the treatment of LKB1-mutant human malignancies [177]. Another study showed that LKB1 was required by Dishevelled (DVL) to inhibit TEAD activity, which facilitated the co-activation of the Wnt/β-catenin and Hippo/YAP pathways [178]. Furthermore, the loss of LKB1 in lung adenocarcinoma cells activated TEAD, which directly transcribed *ZEB2* and repressed DNp63 to regulate cell fate and lineage conversion in lung cancer progression [130]. Similarly, the oncogenic protein Survivin, which is a TEAD target gene, promoted malignant progression of LKB1-deficient lung adenocarcinoma cells [179]. Downstream signaling of LKB1 led to the activation of AMPK, which is a key cellular energy sensor that functions as a tumor suppressor. Similar to LKB1, AMPK activation also inhibited TEAD activity. Upon energy stress, AMPK regulated TEAD by inhibiting YAP via both Hippo-dependent and Hippo-independent mechanisms, which resulted in impaired

tumor growth [49,180,181]. Furthermore, the glucose transporter *GLUT3* is a direct target gene of TEAD. Studies have shown that the glycolytic enzyme PFK1 interacts with TEAD to increase glucose metabolism and tumor growth [49,73]. Further studies on the role of TEAD as a downstream mediator of LKB1-AMPK signaling and energy stress in growth control and cancer metabolism will provide important means of treating LKB1 mutant cancer cells.

6.4. MYC and TEADs

The MYC oncogene is deregulated in >50% of human cancers and its hyperactivation is associated with a poor prognosis and unfavorable patient survival [182]. TEADs have emerged as transcription factors that induce MYC gene expression (Figure 2a). Transcriptome analysis of a Hippo-deficient gastric cancer model showed that TEAD activation directly upregulates MYC and its target genes, which, in turn, induced tumor progression [183]. Similarly, in oral squamous cell carcinoma (OSCC), TEAD induced MYC and BCL-2 gene expression, which accelerated OSCC tumorigenesis [184]. In Drosophila, TEAD has also been shown to transcribe MYC, which induces tissue growth and increased organ size [44]. Furthermore, an in vitro cell competition assay shows that direct TEAD-induced MYC expression is required to become super-competitors, which indicates that TEAD and MYC cooperatively control cell proliferation and cell competition [185]. Despite several studies demonstrating MYC to be a TEAD target gene, MYC is also shown to act in parallel with or upstream of TEAD to modulate cellular function. MYC and TEAD coordinate the gene expression required for cell proliferation upon activation of mitogenic signals. TEADs were found to be constitutively bound to the promoters of the MYC target genes. The subsequent binding of MYC to these sites recruited YAP to bind TEAD, which induced MYC/TEAD target gene expression. This cooperativity between MYC and TEAD induced liver growth and tumorigenesis in mouse models [186]. Notably, the TEAD4-MYCN positive feedback loop was identified to drive high-risk neuroblastoma associated with MYCN amplification [45]. Apart from these reports, TEAD and MYC also showed an anti-correlation in breast cancer patients that enabled the stratification of breast cancer subtypes [187]. Another study also shows that MYC inhibits TEAD transcriptional activity in MYC-driven breast cancer by suppressing the binding between TEAD and YAP/TAZ via AMPK-induced phosphorylation [188]. Similarly, a transcriptional repressor TRPS1 and MYC are commonly co-amplified in breast cancers and TRPS1 inhibits YAP-dependent TEAD activity by direct binding [189]. Collectively, TEAD and MYC form a regulatory feedback mechanism that is important for proper growth control. Thus, further research on the TEAD-MYC circuitry may yield new insights into the treatment of diverse cancer subtypes.

7. Conclusions

In this review, we underscore the molecular mechanisms and functions of TEAD, which is involved in the multistep process of tumor progression, including tumor development, EMT, drug resistance, and metastasis (Figure 2b). Although oncogenic driver mutations in TEAD are yet to be identified, the TEAD transcriptional output was found to be responsible for human malignancies via the crosstalk between various oncogenic signaling pathways and cancer genes such as the Hippo pathway, EGFR-RAS-RAF-MEK pathway, LKB1, GNAQ/11, and MYC (Figure 2a). Despite the emerging role of TEADs as critical effectors in cancer biology, most research regarding TEAD regulation focuses on its major coactivators, YAP and TAZ. YAP/TAZ-independent regulatory mechanisms that govern TEAD activity, which include post-translation modifications, subcellular localizations, and upstream activating and inhibiting stimuli, have been hardly elucidated. Notably, recent studies revealed unprecedented regulatory mechanisms of TEAD such as nucleocytoplasmic shuttling and palmitoylation. These provide the first mechanistic insight in manipulating and targeting TEAD subcellular localization and post-translational modifications to be attractive therapeutic interventions to treat human malignancies. Although flufenamates, originally developed as a COX inhibitor, have been demonstrated to bind and inhibit TEAD functions, additional drugs that specifically bind TEAD with high selectivity and efficacy is yet to be developed. Since TEAD functions as the signaling nexus for critical pathways in

tumor progression, future progress in elucidating regulatory mechanisms of TEAD and developing therapeutic interventions will initiate an exciting new arena for basic science as well as pharmaceutics.

Funding: This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C1560), and the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2018R1C1B6004301) and (NRF-2017R1A4A1015328), and Yonsei University Future leading Research Initiative of 2017 (2017-22-0071) to H.W.P., and the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2014R1A5A2009936) and (NRF-2015R1A2A2A01004240) to H.-S.J., and H.D.H. and D.H.K were supported by the Brain Korea (BK21) PLUS Program.

Acknowledgments: We apologize to those colleagues whose work could not be cited because of space limitations. The authors thank all the members of the TCR laboratory for insightful discussions and critical comments pertaining to this review article.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Yasunami, M.; Suzuki, K.; Ohkubo, H. A novel family of TEA domain-containing transcription factors with distinct spatiotemporal expression patterns. *Biochem. Biophys. Res. Commun.* **1996**, 228, 365–370. [CrossRef] [PubMed]
- 2. Lin, K.C.; Park, H.W.; Guan, K.L. Regulation of the Hippo Pathway Transcription Factor TEAD. *Trends Biochem. Sci.* **2017**, 42, 862–872. [CrossRef] [PubMed]
- 3. Chen, Z.; Friedrich, G.A.; Soriano, P. Transcriptional Enhancer Factor-1 Disruption by a Retroviral Gene Trap Leads to Heart-Defects and Embryonic Lethality in Mice. *Gene Dev.* **1994**, *8*, 2293–2301. [CrossRef] [PubMed]
- 4. Kaneko, K.J.; Kohn, M.J.; Liu, C.; DePamphilis, M.L. Transcription factor TEAD2 is involved in neural tube closure. *Genesis* **2007**, *45*, 577–587. [CrossRef] [PubMed]
- 5. Sawada, A.; Kiyonari, H.; Ukita, K.; Nishioka, N.; Imuta, Y.; Sasaki, H. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. *Mol. Cell Biol.* **2008**, *28*, 3177–3189. [CrossRef] [PubMed]
- 6. Yagi, R.; Kohn, M.J.; Karavanova, I.; Kaneko, K.J.; Vullhorst, D.; DePamphilis, M.L.; Buonanno, A. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. *Development* **2007**, *134*, 3827–3836. [CrossRef]
- 7. Nishioka, N.; Yamamoto, S.; Kiyonari, H.; Sato, H.; Sawada, A.; Ota, M.; Nakao, K.; Sasaki, H. Tead4 is required for specification of trophectoderm in pre-implantation mouse embryos. *Mech. Dev.* **2008**, 125, 270–283. [CrossRef]
- 8. Nishioka, N.; Inoue, K.; Adachi, K.; Kiyonari, H.; Ota, M.; Ralston, A.; Yabuta, N.; Hirahara, S.; Stephenson, R.O.; Ogonuki, N.; et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. *Dev. Cell* 2009, 16, 398–410. [CrossRef]
- 9. Ota, M.; Sasaki, H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. *Development* **2008**, *135*, 4059–4069. [CrossRef]
- 10. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Gene Dev.* 2007, 21, 2747–2761. [CrossRef]
- 11. Jacquemin, P.; Hwang, J.J.; Martial, J.A.; Dolle, P.; Davidson, I. A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain. *J. Biol. Chem.* **1996**, 271, 21775–21785. [CrossRef] [PubMed]
- 12. Jiang, S.W.; Desai, D.; Khan, S.; Eberhardt, N.L. Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation. *DNA Cell. Biol.* **2000**, *19*, 507–514. [CrossRef] [PubMed]
- 13. Anbanandam, A.; Albarado, D.C.; Nguyen, C.T.; Halder, G.; Gao, X.L.; Veeraraghavan, S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17225–17230. [CrossRef] [PubMed]

14. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giulitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in mechanotransduction. *Nature* **2011**, 474, 179–183. [CrossRef] [PubMed]

- 15. Li, X.; Wang, W.Q.; Wang, J.D.; Malovannaya, A.; Xi, Y.X.; Li, W.; Guerra, R.; Hawke, D.H.; Qin, J.; Chen, J.J. Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. *Mol. Syst. Biol.* **2015**, *11*. [CrossRef] [PubMed]
- 16. Xiao, J.H.; Davidson, I.; Matthes, H.; Garnier, J.M.; Chambon, P. Cloning, Expression, and Transcriptional Properties of the Human Enhancer Factor Tef-1. *Cell* **1991**, *65*, 551–568. [CrossRef]
- 17. Zhang, H.; Liu, C.Y.; Zha, Z.Y.; Zhao, B.; Yao, J.; Zhao, S.M.; Xiong, Y.; Lei, Q.Y.; Guan, K.L. TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition. *J. Biol. Chem.* **2009**, *284*, 13355–13362. [CrossRef]
- 18. Zhao, B.; Ye, X.; Yu, J.D.; Li, L.; Li, W.Q.; Li, S.M.; Yu, J.J.; Lin, J.D.; Wang, C.Y.; Chinnaiyan, A.M.; et al. TEAD mediates YAP-dependent gene induction and growth control. *Gene Dev.* **2008**, 22, 1962–1971. [CrossRef]
- 19. Vassilev, A.; Kaneko, K.J.; Shu, H.J.; Zhao, Y.M.; DePamphilis, M.L. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. *Gene Dev.* **2001**, *15*, 1229–1241. [CrossRef]
- 20. Mahoney, W.M.; Hong, J.H.; Yaffe, M.B.; Farrance, K.G. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. *Biochem. J.* **2005**, *388*, 217–225. [CrossRef]
- 21. Chen, H.H.; Maeda, T.; Mullett, S.J.; Stewart, A.F.R. Transcription cofactor Vgl-2 is required for skeletal muscle differentiation. *Genesis* **2004**, *39*, 273–279. [CrossRef] [PubMed]
- 22. Koontz, L.M.; Liu-Chittenden, Y.; Yin, F.; Zheng, Y.G.; Yu, J.Z.; Huang, B.; Chen, Q.; Wu, S.; Pan, D.J. The Hippo Effector Yorkie Controls Normal Tissue Growth by Antagonizing Scalloped-Mediated Default Repression. *Dev. Cell* 2013, 25, 388–401. [CrossRef] [PubMed]
- 23. Chen, H.H.; Mullett, S.J.; Stewart, A.F. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes. *J. Biol. Chem.* **2004**, 279, 30800–30806. [CrossRef] [PubMed]
- 24. Pobbati, A.V.; Chan, S.W.; Lee, I.; Song, H.W.; Hong, W.J. Structural and Functional Similarity between the Vgll1-TEAD and the YAP-TEAD Complexes. *Structure* **2012**, *20*, 1135–1140. [CrossRef] [PubMed]
- 25. Honda, M.; Hidaka, K.; Fukada, S.; Sugawa, R.; Shirai, M.; Ikawa, M.; Morisaki, T. Vestigial-like 2 contributes to normal muscle fiber type distribution in mice. *Sci. Rep.* **2017**, 7. [CrossRef] [PubMed]
- 26. Figeac, N.; Mohamed, A.D.; Sun, C.; Schonfelder, M.; Matallanas, D.; Garcia-Munoz, A.; Missiaglia, E.; Collie-Duguid, E.; De Mello, V.; Pobbati, A.V.; et al. Vgll3 operates via Tead1, Tead3 and Tead4 to influence myogenesis in skeletal muscle. *J. Cell Sci.* **2019**. [CrossRef]
- 27. Kim, M.; Kim, T.; Johnson, R.L.; Lim, D.S. Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZ. *Cell Rep.* **2015**, *11*, 270–282. [CrossRef]
- 28. Galli, G.G.; Carrara, M.; Yuan, W.C.; Valdes-Quezada, C.; Gurung, B.; Pepe-Mooney, B.; Zhang, T.H.; Geeven, G.; Gray, N.S.; de Laat, W.; et al. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. *Mol. Cell* **2015**, *60*, 328–337. [CrossRef]
- 29. Jiao, S.; Li, C.C.; Hao, Q.; Miao, H.F.; Zhang, L.; Li, L.; Zhou, Z.C. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. *Nat. Commun.* **2017**, *8*. [CrossRef]
- Beyer, T.A.; Weiss, A.; Khomchuk, Y.; Huang, K.; Ogunjimi, A.A.; Varelas, X.; Wrana, J.L. Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. *Cell Rep.* 2013, 5, 1611–1624. [CrossRef]
- 31. Liu, X.; Li, H.; Rajurkar, M.; Li, Q.; Cotton, J.L.; Ou, J.; Zhu, L.J.; Goel, H.L.; Mercurio, A.M.; Park, J.S.; et al. Tead and AP1 Coordinate Transcription and Motility. *Cell Rep.* **2016**, *14*, 1169–1180. [CrossRef] [PubMed]
- 32. Zanconato, F.; Forcato, M.; Battilana, G.; Azzolin, L.; Quaranta, E.; Bodega, B.; Rosato, A.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell Biol.* **2015**, *17*, 1218. [CrossRef] [PubMed]
- 33. Kim, T.; Hwang, D.; Lee, D.; Kim, J.H.; Kim, S.Y.; Lim, D.S. MRTF potentiates TEAD-YAP transcriptional activity causing metastasis. *EMBO J.* **2017**, *36*, 520–535. [CrossRef] [PubMed]
- 34. Park, H.W.; Kim, Y.C.; Yu, B.; Moroishi, T.; Mo, J.S.; Plouffe, S.W.; Meng, Z.P.; Lin, K.C.; Yu, F.X.; Alexander, C.M.; et al. Alternative Wnt Signaling Activates YAP/TAZ. *Cell* **2015**, *162*, 780–794. [CrossRef]

35. Seo, E.; Basu-Roy, U.; Gunaratne, P.H.; Coarfa, C.; Lim, D.S.; Basilico, C.; Mansukhani, A. SOX2 Regulates YAP1 to Maintain Stemness and Determine Cell Fate in the Osteo-Adipo Lineage. *Cell Rep.* **2013**, *3*, 2075–2087. [CrossRef]

- 36. Lee, D.H.; Park, J.O.; Kim, T.S.; Kim, S.K.; Kim, T.H.; Kim, M.C.; Park, G.S.; Kim, J.H.; Kuninaka, S.; Olson, E.N.; et al. LATS-YAP/TAZ controls lineage specification by regulating TGF beta signaling and Hnf4 alpha expression during liver development. *Nat. Commun.* 2016, 7. [CrossRef]
- 37. Lai, D.; Yang, X.L. BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. *Cell Signal.* **2013**, *25*, 1720–1728. [CrossRef]
- 38. Zhang, J.M.; Ji, J.Y.; Yu, M.; Overholtzer, M.; Smolen, G.A.; Wang, R.; Brugge, J.S.; Dyson, N.J.; Haber, D.A. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. *Nat. Cell Biol.* **2009**, *11*, 1444–1450. [CrossRef]
- 39. Song, S.M.; Honjo, S.; Jin, J.K.; Chang, S.S.; Scott, A.W.; Chen, Q.R.; Kalhor, N.; Correa, A.M.; Hofstetter, W.L.; Albarracin, C.T.; et al. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. *Clin. Cancer Res.* **2015**, *21*, 2580–2590. [CrossRef]
- 40. Feng, J.; Yang, H.; Zhang, Y.; Wei, H.; Zhu, Z.; Zhu, B.; Yang, M.; Cao, W.; Wang, L.; Wu, Z. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. *Oncogene* **2017**, *36*, 5829–5839. [CrossRef]
- 41. Kim, M.H.; Kim, C.G.; Kim, S.K.; Shin, S.J.; Choe, E.A.; Park, S.H.; Shin, E.C.; Kim, J. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. *Cancer Immunol. Res.* **2018**, *6*, 255–266. [CrossRef] [PubMed]
- 42. Van Rensburg, H.J.J.; Azad, T.; Ling, M.; Hao, Y.W.; Snetsinger, B.; Khanal, P.; Minassian, L.M.; Graham, C.H.; Rauh, M.J.; Yang, X.L. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. *Cancer Res.* 2018, 78, 1457–1470. [CrossRef] [PubMed]
- 43. Miao, J.B.; Hsu, P.C.; Yang, Y.L.; Xu, Z.D.; Dai, Y.Y.; Wang, Y.C.; Chan, G.; Huang, Z.; Hu, B.; Li, H.; et al. YAP regulates PD-L1 expression in human NSCLC cells. *Oncotarget* 2017, 8, 114576–114587. [CrossRef] [PubMed]
- 44. Neto-Silva, R.M.; de Beco, S.; Johnston, L.A. Evidence for a Growth-Stabilizing Regulatory Feedback Mechanism between Myc and Yorkie, the Drosophila Homolog of Yap. *Dev. Cell* **2010**, *19*, 507–520. [CrossRef] [PubMed]
- 45. Rajbhandari, P.; Lopez, G.; Capdevila, C.; Salvatori, B.; Yu, J.Y.; Rodriguez-Barrueco, R.; Martinez, D.; Yarmarkovich, M.; Weichert-Leahey, N.; Abraham, B.J.; et al. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. *Cancer Discov.* 2018, 8, 582–599. [CrossRef] [PubMed]
- 46. Moroishi, T.; Park, H.W.; Qin, B.D.; Chen, Q.; Meng, Z.P.; Plouffe, S.W.; Taniguchi, K.; Yu, F.X.; Karin, M.; Pan, D.J.; et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. *Gene Dev.* **2015**, 29, 1271–1284. [CrossRef] [PubMed]
- 47. Park, Y.Y.; Sohn, B.H.; Johnson, R.L.; Kang, M.H.; Kim, S.B.; Shim, J.J.; Mangala, L.S.; Kim, J.H.; Yoo, J.E.; Rodriguez-Aguayo, C.; et al. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. *Hepatology* **2016**, *63*, 159–172. [CrossRef] [PubMed]
- 48. Hansen, C.G.; Ng, Y.L.D.; Lam, W.L.M.; Plouffe, S.W.; Guan, K.L. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. *Cell Res.* **2015**, 25, 1299–1313. [CrossRef]
- 49. Wang, W.; Xiao, Z.D.; Li, X.; Aziz, K.E.; Gan, B.; Johnson, R.L.; Chen, J. AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat. Cell Biol.* **2015**, *17*, 490–499. [CrossRef]
- 50. Holden, J.K.; Cunningham, C.N. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors. *Cancers* **2018**, *10*. [CrossRef]
- 51. Park, J.H.; Shin, J.E.; Park, H.W. The Role of Hippo Pathway in Cancer Stem Cell Biology. *Mol. Cells* **2018**, *41*, 83–92. [CrossRef] [PubMed]
- 52. Moya, I.M.; Halder, G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. *Nat. Rev. Mol. Cell Biol.* **2018**. [CrossRef] [PubMed]
- 53. Moon, S.; Yeon Park, S.; Woo Park, H. Regulation of the Hippo pathway in cancer biology. *Cell Mol. Life Sci.* **2018**, 75, 2303–2319. [CrossRef] [PubMed]
- 54. Kim, C.L.; Choi, S.H.; Mo, J.S. Role of the Hippo Pathway in Fibrosis and Cancer. Cells 2019, 8. [CrossRef]

55. Meng, Z.P.; Moroishi, T.; Guan, K.L. Mechanisms of Hippo pathway regulation. *Gene Dev.* **2016**, *30*, 1–17. [CrossRef] [PubMed]

- 56. Yu, F.X.; Guan, K.L. The Hippo pathway: regulators and regulations. *Gene Dev.* **2013**, 27, 355–371. [CrossRef] [PubMed]
- 57. Pavel, M.; Renna, M.; Park, S.J.; Menzies, F.M.; Ricketts, T.; Fullgrabe, J.; Ashkenazi, A.; Frake, R.A.; Lombarte, A.C.; Bento, C.F.; et al. Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis. *Nat. Commun.* **2018**, *9*. [CrossRef] [PubMed]
- 58. Liang, N.; Zhang, C.; Dill, P.; Panasyuk, G.; Pion, D.; Koka, V.; Gallazzini, M.; Olson, E.N.; Lam, H.; Henske, E.P.; et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J. Exp. Med.* **2014**, 211, 2249–2263. [CrossRef]
- 59. Liu, C.Y.; Zha, Z.Y.; Zhou, X.; Zhang, H.; Huang, W.; Zhao, D.; Li, T.T.; Chan, S.W.; Lim, C.J.; Hong, W.J.; et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCF beta-TrCP E3 Ligase. *J. Biol. Chem.* **2010**, *285*, 37159–37169. [CrossRef]
- 60. Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.Y.; Guan, K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF beta-TRCP. *Gene Dev.* **2010**, 24, 72–85. [CrossRef]
- 61. Stein, C.; Bardet, A.F.; Roma, G.; Bergling, S.; Clay, I.; Ruchti, A.; Agarinis, C.; Schmelzle, T.; Bouwmeester, T.; Schubeler, D.; et al. YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. *PLoS Genet.* **2015**, *11*. [CrossRef] [PubMed]
- 62. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.J.; Anders, R.A.; Liu, J.O.; Pan, D.J. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Gene Dev.* **2012**, *26*, 1300–1305. [CrossRef] [PubMed]
- 63. Lin, K.C.; Moroishi, T.; Meng, Z.P.; Jeong, H.S.; Plouffe, S.W.; Sekido, Y.; Han, J.H.; Park, H.W.; Guan, K.L. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. *Nat. Cell Biol.* **2017**, *19*, 996. [CrossRef] [PubMed]
- 64. Chan, S.W.; Lim, C.J.; Loo, L.S.; Chong, Y.F.; Huang, C.X.; Hong, W.J. TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation. *J. Biol. Chem.* **2009**, *284*, 14347–14358. [CrossRef] [PubMed]
- 65. Diepenbruck, M.; Waldmeier, L.; Ivanek, R.; Berninger, P.; Arnold, P.; van Nimwegen, E.; Christofori, G. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. *J. Cell Sci.* 2014, 127, 1523–1536. [CrossRef] [PubMed]
- He, C.B.; Mao, D.G.; Hua, G.H.; Lv, X.M.; Chen, X.C.; Angeletti, P.C.; Dong, J.X.; Remmenga, S.W.; Rodabaugh, K.J.; Zhou, J.; et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. *EMBO Mol. Med.* 2015, 7, 1426–1449. [CrossRef]
- 67. Fan, R.; Kim, N.G.; Gumbiner, B.M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 2569–2574. [CrossRef]
- 68. Samanta, S.; Guru, S.; Elaimy, A.L.; Amante, J.J.; Ou, J.H.; Yu, J.; Zhu, L.H.J.; Mercurio, A.M. IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer. *Cell Rep.* **2018**, 23, 2559–2567. [CrossRef]
- 69. Zhang, S.P.; Zhang, H.; Ghia, E.M.; Huang, J.J.; Wu, L.F.; Zhang, J.C.; Lam, S.; Lei, Y.; He, J.S.; Cui, B.; et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 1370–1377. [CrossRef]
- 70. Pefani, D.E.; Pankova, D.; Abraham, A.G.; Grawenda, A.M.; Vlahov, N.; Scrace, S.; E, O.N. TGF-beta Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. *Mol. Cell* **2016**, *63*, 156–166. [CrossRef]
- 71. Varelas, X.; Sakuma, R.; Samavarchi-Tehrani, P.; Peerani, R.; Rao, B.M.; Dembowy, J.; Yaffe, M.B.; Zandstra, P.W.; Wrana, J.L. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. *Nat. Cell Biol.* **2008**, *10*, 837–848. [CrossRef]
- 72. Hiemer, S.E.; Szymaniak, A.D.; Varelas, X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. *J. Biol. Chem.* **2014**, 289, 13461–13474. [CrossRef]
- 73. Enzo, E.; Santinon, G.; Pocaterra, A.; Aragona, M.; Bresolin, S.; Forcato, M.; Grifoni, D.; Pession, A.; Zanconato, F.; Guzzo, G.; et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. *EMBO J.* **2015**, *34*, 1349–1370. [CrossRef] [PubMed]

74. Dai, X.M.; Liu, H.; Shen, S.Y.; Guo, X.C.; Yan, H.; Ji, X.Y.; Li, L.; Huang, J.; Feng, X.H.; Zhao, B. YAP activates the Hippo pathway in a negative feedback loop. *Cell Res.* **2015**, *25*, 1175–1178. [CrossRef] [PubMed]

- 75. Azzolin, L.; Zanconato, F.; Bresolin, S.; Forcato, M.; Basso, G.; Bicciato, S.; Cordenonsi, M.; Piccolo, S. Role of TAZ as Mediator of Wnt Signaling. *Cell* **2012**, *151*, 1443–1456. [CrossRef] [PubMed]
- 76. Azzolin, L.; Panciera, T.; Soligo, S.; Enzo, E.; Bicciato, S.; Dupont, S.; Bresolin, S.; Frasson, C.; Basso, G.; Guzzardo, V.; et al. YAP/TAZ Incorporation in the beta-Catenin Destruction Complex Orchestrates the Wnt Response. *Cell* **2014**, *158*, 157–170. [CrossRef]
- 77. Cai, J.; Maitra, A.; Anders, R.A.; Taketo, M.M.; Pan, D.J. beta-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. *Gene Dev.* **2015**, *29*, 1493–1506. [CrossRef] [PubMed]
- 78. Feng, Y.; Liang, Y.; Zhu, X.; Wang, M.; Gui, Y.; Lu, Q.; Gu, M.; Xue, X.; Sun, X.; He, W.; et al. The signaling protein Wnt5a promotes TGFbeta1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz. *J. Biol. Chem.* **2018**, 293, 19290–19302. [CrossRef]
- 79. Wang, C.; Han, X.; Zhou, Z.; Uyunbilig, B.; Huang, X.; Li, R.; Li, X. Wnt3a Activates the WNT-YAP/TAZ Pathway to Sustain CDX2 Expression in Bovine Trophoblast Stem Cells. *DNA Cell Biol.* **2019**. [CrossRef]
- 80. Estaras, C.; Hsu, H.T.; Huang, L.; Jones, K.A. YAP repression of the WNT3 gene controls hESC differentiation along the cardiac mesoderm lineage. *Genes Dev.* **2017**, *31*, 2250–2263. [CrossRef]
- 81. Gregorieff, A.; Liu, Y.; Inanlou, M.R.; Khomchuk, Y.; Wrana, J.L. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. *Nature* **2015**, *526*, *715–718*. [CrossRef] [PubMed]
- 82. Barry, E.R.; Morikawa, T.; Butler, B.L.; Shrestha, K.; de la Rosa, R.; Yan, K.S.; Fuchs, C.S.; Magness, S.T.; Smits, R.; Ogino, S.; et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. *Nature* 2013, 493, 106. [CrossRef] [PubMed]
- 83. Qin, H.; Hejna, M.; Liu, Y.X.; Percharde, M.; Wossidlo, M.; Blouin, L.; Durruthy-Durruthy, J.; Wong, P.; Qi, Z.X.; Yu, J.W.; et al. YAP Induces Human Naive Pluripotency. *Cell Rep.* **2016**, *14*, 2301–2312. [CrossRef] [PubMed]
- 84. Miranda, M.Z.; Bialik, J.F.; Speight, P.; Dan, Q.; Yeung, T.; Szaszi, K.; Pedersen, S.F.; Kapus, A. TGF-beta1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism. *J. Biol. Chem.* **2017**, 292, 14902–14920. [CrossRef] [PubMed]
- 85. Kimura, T.E.; Duggirala, A.; Smith, M.C.; White, S.; Sala-Newby, G.B.; Newby, A.C.; Bond, M. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP. *J. Mol. Cell Cardiol.* **2016**, 90, 1–10. [CrossRef]
- 86. Varelas, X.; Samavarchi-Tehrani, P.; Narimatsu, M.; Weiss, A.; Cockburn, K.; Larsen, B.G.; Rossant, J.; Wrana, J.L. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. *Dev. Cell* **2010**, *19*, 831–844. [CrossRef]
- 87. Estaras, C.; Benner, C.; Jones, K.A. SMADs and YAP compete to control elongation of beta-catenin:LEF-1-recruited RNAPII during hESC differentiation. *Mol. Cell* **2015**, *58*, 780–793. [CrossRef]
- 88. Fujii, M.; Toyoda, T.; Nakanishi, H.; Yatabe, Y.; Sato, A.; Matsudaira, Y.; Ito, H.; Murakami, H.; Kondo, Y.; Kondo, E.; et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. *J. Exp. Med.* **2012**, 209, 479–494. [CrossRef]
- 89. Lin, K.C.; Moroishi, T.; Meng, Z.P.; Jeong, H.S.; Plouffe, S.W.; Sekido, Y.; Han, J.H.; Park, H.W.; Guan, K.L. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation (vol 19, pg 996, 2017). *Nat. Cell Biol.* **2018**, 20, 1098. [CrossRef]
- 90. Home, P.; Saha, B.; Ray, S.; Dutta, D.; Gunewardena, S.; Yoo, B.; Pal, A.; Vivian, J.L.; Larson, M.; Petroff, M.; et al. Altered subcellular localization of transcription factor TEAD4 regulates first mammalian cell lineage commitment. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 7362–7367. [CrossRef]
- 91. Hirate, Y.; Cockburn, K.; Rossant, J.; Sasaki, H. Tead4 is constitutively nuclear, while nuclear vs. cytoplasmic Yap distribution is regulated in preimplantation mouse embryos. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E3389–E3390. [CrossRef] [PubMed]
- 92. Qi, Y.F.; Yu, J.; Han, W.; Fan, X.J.; Qian, H.L.; Wei, H.H.; Tsai, Y.H.S.; Zhao, J.Y.; Zhang, W.J.; Liu, Q.T.; et al. A splicing isoform of TEAD4 attenuates the Hippo-YAP signalling to inhibit tumour proliferation. *Nat. Commun.* 2016, 7. [CrossRef] [PubMed]

93. De Nadal, E.; Ammerer, G.; Posas, F. Controlling gene expression in response to stress. *Nat. Rev. Genet.* **2011**, 12, 833–845. [CrossRef] [PubMed]

- 94. Hong, A.W.; Meng, Z.P.; Yuan, H.X.; Plouffe, S.W.; Moon, S.; Kim, W.; Jho, E.H.; Guan, K.L. Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. *EMBO Rep.* **2017**, *18*, 72–86. [CrossRef] [PubMed]
- 95. Moon, S.; Kim, W.; Kim, S.; Kim, Y.; Song, Y.; Bilousov, O.; Kim, J.; Lee, T.; Cha, B.; Kim, M.; et al. Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization. *EMBO Rep.* **2017**, *18*, 61–71. [CrossRef]
- 96. Gupta, M.P.; Kogut, P.; Gupta, M. Protein kinase-A dependent phosphorylation of transcription enhancer factor-1 represses its DNA-binding activity but enhances its gene activation ability. *Nucleic Acids Res.* **2000**, 28, 3168–3177. [CrossRef]
- 97. Jiang, S.W.; Dong, M.Q.; Trujillo, M.A.; Miller, L.J.; Eberhardt, N.L. DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells. *J. Biol. Chem.* **2001**, 276, 23464–23470. [CrossRef]
- 98. Chan, P.; Han, X.; Zheng, B.; DeRan, M.; Yu, J.; Jarugumilli, G.K.; Deng, H.; Pan, D.; Luo, X.; Wu, X. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. *Nat. Chem. Biol.* **2016**, *12*, 282–289. [CrossRef]
- 99. Noland, C.L.; Gierke, S.; Schnier, P.D.; Murray, J.; Sandoval, W.N.; Sagolla, M.; Dey, A.; Hannoush, R.N.; Fairbrother, W.J.; Cunningham, C.N. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. *Structure* **2016**, *24*, 179–186. [CrossRef]
- 100. Mesrouze, Y.; Meyerhofer, M.; Bokhovchuk, F.; Fontana, P.; Zimmermann, C.; Martin, T.; Delaunay, C.; Izaac, A.; Kallen, J.; Schmelzle, T.; et al. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ. *Protein Sci.* **2017**, *26*, 2399–2409. [CrossRef]
- 101. Resh, M.D. Palmitoylation of ligands, receptors, and intracellular signaling molecules. *Sci. STKE* **2006**, 2006, re14. [CrossRef] [PubMed]
- 102. Kim, N.G.; Gumbiner, B.M. Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 9877–9882. [CrossRef] [PubMed]
- 103. Pobbati, A.V.; Han, X.; Hung, A.W.; Weiguang, S.; Huda, N.; Chen, G.Y.; Kang, C.B.; Chia, C.S.B.; Luo, X.L.; Hong, W.J.; et al. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. *Structure* **2015**, *23*, 2076–2086. [CrossRef] [PubMed]
- 104. Pobbati, A.V.; Hong, W. Emerging roles of TEAD transcription factors and its coactivators in cancers. *Cancer Biol. Ther.* **2013**, *14*, 390–398. [CrossRef] [PubMed]
- 105. Knight, J.F.; Shepherd, C.J.; Rizzo, S.; Brewer, D.; Jhavar, S.; Dodson, A.R.; Cooper, C.S.; Eeles, R.; Falconer, A.; Kovacs, G.; et al. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. *Br. J. Cancer* 2008, 99, 1849–1858. [CrossRef]
- 106. Liang, K.; Zhou, G.X.; Zhang, Q.; Li, J.; Zhang, C.P. Expression of Hippo Pathway in Colorectal Cancer. *Saudi J. Gastroentero* **2014**, *20*, 188–194. [CrossRef]
- 107. Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C.Y.; Cui, L. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. *Oncogene* **2016**, *35*, 2789–2800. [CrossRef]
- 108. Zhou, Y.; Huang, T.; Zhang, J.; Wong, C.C.; Zhang, B.; Dong, Y.; Wu, F.; Tong, J.H.M.; Wu, W.K.K.; Cheng, A.S.L.; et al. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. *Oncogene* 2017, 36, 6518–6530. [CrossRef]
- 109. Zhou, G.X.; Li, X.Y.; Zhang, Q.; Zhao, K.; Zhang, C.P.; Xue, C.H.; Yang, K.; Tian, Z.B. Effects of the Hippo Signaling Pathway in Human Gastric Cancer. *Asian Pac. J. Cancer Prev.* **2013**, *14*, 5199–5205. [CrossRef]
- 110. Han, W.; Jung, E.M.; Cho, J.; Lee, J.W.; Hwang, K.T.; Yang, S.J.; Kang, J.J.; Bae, J.Y.; Jeon, Y.K.; Park, I.A.; et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. *Gene Chromosome Cancer* **2008**, *47*, 490–499. [CrossRef]
- 111. Wang, C.Y.; Nie, Z.; Zhou, Z.M.; Zhang, H.L.; Liu, R.; Wu, J.; Qin, J.Y.; Ma, Y.; Chen, L.; Li, S.M.; et al. The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27(Kip1). *Oncotarget* 2015, 6, 17685–17697. [CrossRef] [PubMed]

112. Korkola, J.E.; Houldsworth, J.; Chadalavada, R.S.V.; Olshen, A.B.; Dobrzynski, D.; Reuter, V.E.; Bosl, G.J.; Chaganti, R.S.K. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. *Cancer Res.* **2006**, *66*, 820–827. [CrossRef]

- 113. Skotheim, R.I.; Autio, R.; Lind, G.E.; Kraggerud, S.M.; Andrews, P.W.; Monni, O.; Kallioniemi, O.; Lothe, R.A. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. *Cell Oncol.* **2006**, *28*, 315–326. [PubMed]
- 114. Zhang, W.; Li, J.; Wu, Y.P.; Ge, H.; Song, Y.; Wang, D.M.; Yuan, H.; Jiang, H.B.; Wang, Y.L.; Cheng, J. TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma. *Cancer Cell Int.* **2018**, *18*. [CrossRef]
- 115. Schutte, U.; Bisht, S.; Heukamp, L.C.; Kebschull, M.; Florin, A.; Haarmann, J.; Hoffmann, P.; Bendas, G.; Buettner, R.; Brossart, P.; et al. Hippo Signaling Mediates Proliferation, Invasiveness, and Metastatic Potential of Clear Cell Renal Cell Carcinoma. *Transl. Oncol.* **2014**, *7*, 309–321. [CrossRef] [PubMed]
- 116. Fernandez, A.; Northcott, P.A.; Dalton, J.; Fraga, C.; Ellison, D.; Angers, S.; Taylor, M.D.; Kenney, A.M. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. *Gene Dev.* 2009, 23, 2729–2741. [CrossRef]
- 117. Bokhovchuk, F.; Mesrouze, Y.; Izaac, A.; Meyerhofer, M.; Zimmermann, C.; Fontana, P.; Schmelzle, T.; Erdmann, D.; Furet, P.; Kallen, J.; et al. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy. *FEBS J.* **2019**. [CrossRef]
- 118. Fossdal, R.; Jonasson, F.; Kristjansdottir, G.T.; Kong, A.; Stefansson, H.; Gosh, S.; Gulcher, J.R.; Stefansson, K. A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). *Hum. Mol. Genet.* **2004**, *13*, 975–981. [CrossRef]
- 119. Sun, Z.Q.; Xu, R.W.; Li, X.Y.; Ren, W.G.; Ou, C.L.; Wang, Q.S.; Zhang, H.; Zhang, X.M.; Ma, J.; Wang, H.J.; et al. Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis. *PLoS ONE* **2015**, *10*. [CrossRef]
- 120. Feng, J.T.; Ren, P.W.; Gou, J.H.; Li, Z.Y. Prognostic significance of TAZ expression in various cancers: A meta-analysis. *Oncotargets Ther.* **2016**, *9*, 5235–5244. [CrossRef]
- 121. Jiao, S.; Wang, H.Z.; Shi, Z.B.; Dong, A.M.; Zhang, W.J.; Song, X.M.; He, F.; Wang, Y.C.; Zhang, Z.Z.; Wang, W.J.; et al. A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. *Cancer Cell* 2014, 25, 166–180. [CrossRef] [PubMed]
- 122. Park, H.W.; Guan, K.L. Regulation of the Hippo pathway and implications for anticancer drug development. *Trends Pharm. Sci.* **2013**, *34*, 581–589. [CrossRef] [PubMed]
- 123. Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* **2017**, *14*, 611–629. [CrossRef] [PubMed]
- 124. Overholtzer, M.; Zhang, J.; Smolen, G.A.; Muir, B.; Li, W.; Sgroi, D.C.; Deng, C.X.; Brugge, J.S.; Haber, D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. *Proc. Natl. Acad. Sci. USA* 2006, 103, 12405–12410. [CrossRef] [PubMed]
- 125. Lei, Q.Y.; Zhang, H.; Zhao, B.; Zha, Z.Y.; Bai, F.; Pei, X.H.; Zhao, S.; Xiong, Y.; Guan, K.L. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. *Mol. Cell Biol.* **2008**, 28, 2426–2436. [CrossRef] [PubMed]
- 126. Lamar, J.M.; Stern, P.; Liu, H.; Schindler, J.W.; Jiang, Z.G.; Hynes, R.O. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E2441–E2450. [CrossRef]
- 127. Vincent-Mistiaen, Z.; Elbediwy, A.; Vanyai, H.; Cotton, J.; Stamp, G.; Nye, E.; Spencer-Dene, B.; Thomas, G.J.; Mao, J.H.; Thompson, B. YAP drives cutaneous squamous cell carcinoma formation and progression. *eLife* **2018**, 7. [CrossRef] [PubMed]
- 128. Yu, M.X.; Chen, Y.Z.; Li, X.L.; Yang, R.; Zhang, L.J.; Huangfu, L.T.; Zheng, N.; Zhao, X.G.; Lv, L.F.; Hong, Y.Z.; et al. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. *Cell Death Dis.* 2018, 9. [CrossRef]
- 129. Lehmann, W.; Mossmann, D.; Kleemann, J.; Mock, K.; Meisinger, C.; Brummer, T.; Herr, R.; Brabletz, S.; Stemmler, M.P.; Brabletz, T. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. *Nat. Commun.* **2016**, *7*. [CrossRef]

130. Gao, Y.J.; Zhang, W.J.; Han, X.K.; Li, F.M.; Wang, X.J.; Wang, R.; Fang, Z.Y.; Tong, X.Y.; Yao, S.; Li, F.; et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression (vol 5, 4629, 2014). *Nat. Commun.* **2015**, *6*. [CrossRef]

- 131. Haemmerle, M.; Taylor, M.L.; Gutschner, T.; Pradeep, S.; Cho, M.S.; Sheng, J.T.; Lyons, Y.M.; Nagaraja, A.S.; Dood, R.L.; Wen, Y.F.; et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. *Nat. Commun.* **2017**, *8*. [CrossRef] [PubMed]
- 132. Zhao, B.; Li, L.; Wang, L.; Wang, C.Y.; Yu, J.D.; Guan, K.L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. *Gene Dev.* **2012**, *26*, 54–68. [CrossRef] [PubMed]
- 133. Lee, H.J.; Diaz, M.F.; Price, K.M.; Ozuna, J.A.; Zhang, S.L.; Sevick-Muraca, E.M.; Hagan, J.P.; Wenzel, P.L. Fluid shear stress activates YAP1 to promote cancer cell motility. *Nat. Commun.* **2017**, *8*. [CrossRef] [PubMed]
- 134. Chen, D.H.; Sun, Y.T.; Wei, Y.K.; Zhang, P.J.; Rezaeian, A.H.; Teruya-Feldstein, J.; Gupta, S.; Liang, H.; Lin, H.K.; Hung, M.C.; et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. *Nat. Med.* 2012, 18, 1511–1517. [CrossRef] [PubMed]
- 135. Guo, P.D.; Lu, X.X.; Gan, W.J.; Li, X.M.; He, X.S.; Zhang, S.; Ji, Q.H.; Zhou, F.; Cao, Y.; Wang, J.R.; et al. RAR gamma Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway. *Cancer Res.* **2016**, *76*, 3813–3825. [CrossRef] [PubMed]
- 136. Li, C.; Wang, S.; Xing, Z.; Lin, A.; Liang, K.; Song, J.; Hu, Q.; Yao, J.; Chen, Z.; Park, P.K.; et al. A ROR1-HER3-IncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. *Nat. Cell Biol.* **2017**, *19*, 106–119. [CrossRef] [PubMed]
- 137. Lamar, J.M.; Xiao, Y.; Norton, E.; Jiang, Z.G.; Gerhard, G.M.; Kooner, S.; Warren, J.S.A.; Hynes, R.O. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis. *J. Biol. Chem.* **2019**, *294*, 2302–2317. [CrossRef] [PubMed]
- 138. Qiao, Y.T.; Chen, J.X.; Lim, Y.B.; Finch-Edmondson, M.L.; Seshachalam, V.P.; Qin, L.; Jiang, T.; Low, B.C.; Singh, H.; Lim, C.T.; et al. YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis. *Cell Rep.* **2017**, *19*, 1495–1502. [CrossRef] [PubMed]
- 139. Er, E.E.; Valiente, M.; Ganesh, K.; Zou, Y.L.; Agrawal, S.; Hu, J.; Griscom, B.; Rosenblum, M.; Boire, A.; Brogi, E.; et al. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization (vol 20, pg 966, 2018). *Nat. Cell Biol.* **2019**, 21, 408. [CrossRef]
- 140. Lin, K.C.; Park, H.W.; Guan, K.L. Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer. *Annu. Rev. Cancer Biol.* **2018**, 2, 59–79. [CrossRef]
- 141. Sourbier, C.; Liao, P.J.; Ricketts, C.J.; Wei, D.; Yang, Y.; Baranes, S.M.; Gibbs, B.K.; Ohanjanian, L.; Spencer Krane, L.; Scroggins, B.T.; et al. Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. *Oncotarget* **2018**, *9*, 10723–10733. [CrossRef] [PubMed]
- 142. Rouleau, G.A.; Merel, P.; Lutchman, M.; Sanson, M.; Zucman, J.; Marineau, C.; Hoang-Xuan, K.; Demczuk, S.; Desmaze, C.; Plougastel, B.; et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. *Nature* **1993**, *363*, 515–521. [CrossRef] [PubMed]
- 143. Woodard, G.A.; Yang, Y.L.; You, L.; Jablons, D.M. Drug development against the hippo pathway in mesothelioma. *Transl. Lung Cancer Res.* **2017**, *6*, 335–342. [CrossRef] [PubMed]
- 144. Abdollahpour, H.; Appaswamy, G.; Kotlarz, D.; Diestelhorst, J.; Beier, R.; Schaffer, A.A.; Gertz, E.M.; Schambach, A.; Kreipe, H.H.; Pfeifer, D.; et al. The phenotype of human STK4 deficiency. *Blood* **2012**, *119*, 3450–3457. [CrossRef] [PubMed]
- 145. Seidel, C.; Schagdarsurengin, U.; Blumke, K.; Wurl, P.; Pfeifer, G.P.; Hauptmann, S.; Taubert, H.; Dammann, R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. *Mol. Carcinog.* **2007**, *46*, 865–871. [CrossRef]
- 146. Tapon, N.; Harvey, K.F.; Bell, D.W.; Wahrer, D.C.R.; Schiripo, T.A.; Haber, D.A.; Hariharan, I.K. salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. *Cell* **2002**, *110*, 467–478. [CrossRef]
- 147. Lai, Z.C.; Wei, X.M.; Shimizu, T.; Ramos, E.; Rohrbaugh, M.; Nikolaidis, N.; Ho, L.L.; Li, Y. Control of cell proliferation and apoptosis by Mob as tumor suppressor, Mats. *Cell* **2005**, *120*, 675–685. [CrossRef]
- 148. Rutherford, S.; Yu, Y.T.; Rumpel, C.A.; Frierson, H.F.; Moskaluk, C.A. Chromosome 6 deletion and candidate tumor suppressor genes in adenoid cystic carcinoma. *Cancer Lett.* **2006**, *236*, 309–317. [CrossRef]
- 149. Saadeldin, M.K.; Shawer, H.; Mostafa, A.; Kassem, N.M.; Amleh, A.; Siam, R. New genetic variants of LATS1 detected in urinary bladder and colon cancer. *Front. Genet.* **2015**, *5*. [CrossRef]

150. Oh, J.E.; Ohta, T.; Satomi, K.; Foll, M.; Durand, G.; McKay, J.; Le Calvez-Kelm, F.; Mittelbronn, M.; Brokinkel, B.; Paulus, W.; et al. Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas. *J. Neuropath. Exp. Neur.* **2015**, 74, 952–959. [CrossRef]

- 151. Bonilla, X.; Parmentier, L.; King, B.; Bezrukov, F.; Kaya, G.; Zoete, V.; Seplyarskiy, V.B.; Sharpe, H.J.; McKee, T.; Letourneau, A.; et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. *Nat. Genet.* **2016**, *48*, 398. [CrossRef] [PubMed]
- 152. Jiang, Z.; Li, X.; Hu, J.; Zhou, W.; Jiang, Y.; Li, G.; Lu, D. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. *Neurosci. Res.* **2006**, *56*, 450–458. [CrossRef] [PubMed]
- 153. Kuijjer, M.L.; Rydbeck, H.; Kresse, S.H.; Buddingh, E.P.; Roelofs, H.; Burger, H.; Myklebost, O.; Hogendoorn, P.C.W.; Meza-Zepeda, L.A.; Cleton-Jansen, A.M. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. *Cancer Res.* **2012**, 72. [CrossRef]
- 154. Miyanaga, A.; Masuda, M.; Tsuta, K.; Kawasaki, K.; Nakamura, Y.; Sakuma, T.; Asamura, H.; Gemma, A.; Yamada, T. Hippo Pathway Gene Mutations in Malignant Mesothelioma Revealed by RNA and Targeted Exon Sequencing. *J. Thorac. Oncol.* **2015**, *10*, 844–851. [CrossRef] [PubMed]
- 155. Takahashi, Y.; Miyoshi, Y.; Takahata, C.; Irahara, N.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. *Clin. Cancer Res.* **2005**, *11*, 1380–1385. [CrossRef] [PubMed]
- 156. Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenauf, A.C.; Wackernagel, W.; Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. *N. Engl. J. Med.* **2010**, 363, 2191–2199. [CrossRef] [PubMed]
- 157. Yu, F.X.; Luo, J.; Mo, J.S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* **2014**, 25, 822–830. [CrossRef] [PubMed]
- 158. Zhang, X.; Tang, J.Z.; Vergara, I.A.; Zhang, Y.; Szeto, P.; Yang, L.; Mintoff, C.; Colebatch, A.; McIntosh, L.; Mitchell, K.A.; et al. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. *Mol. Cancer Res.* **2019**. [CrossRef]
- 159. Menzel, M.; Meckbach, D.; Weide, B.; Toussaint, N.C.; Schilbach, K.; Noor, S.; Eigentler, T.; Ikenberg, K.; Busch, C.; Quintanilla-Martinez, L.; et al. In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. *Pigm. Cell Melanoma R* **2014**, 27. [CrossRef] [PubMed]
- 160. Chen, H.Y.; Yu, S.L.; Ho, B.C.; Su, K.Y.; Hsu, Y.C.; Chang, C.S.; Li, Y.C.; Yang, S.Y.; Hsu, P.Y.; Ho, H.; et al. R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. *J. Clin. Oncol.* 2015, 33, 2303–2310. [CrossRef]
- 161. Tanas, M.R.; Sboner, A.; Oliveira, A.M.; Erickson-Johnson, M.R.; Hespelt, J.; Hanwright, P.J.; Flanagan, J.; Luo, Y.; Fenwick, K.; Natrajan, R.; et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Sci. Transl. Med.* **2011**, *3*, 98ra82. [CrossRef] [PubMed]
- 162. Errani, C.; Zhang, L.; Sung, Y.S.; Hajdu, M.; Singer, S.; Maki, R.G.; Healey, J.H.; Antonescu, C.R. A Novel WWTR1-CAMTA1 Gene Fusion Is a Consistent Abnormality in Epithelioid Hemangioendothelioma of Different Anatomic Sites. *Gene Chromosome Cancer* **2011**, *50*, 644–653. [CrossRef] [PubMed]
- 163. Antonescu, C.R.; Le Loarer, F.; Mosquera, J.M.; Sboner, A.; Zhang, L.; Chen, C.L.; Chen, H.W.; Pathan, N.; Krausz, T.; Dickson, B.C.; et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. *Gene Chromosome Cancer* 2013, 52, 775–784. [CrossRef] [PubMed]
- 164. Sekine, S.; Kiyono, T.; Ryo, E.; Ogawa, R.; Wakai, S.; Ichikawa, H.; Suzuki, K.; Arai, S.; Tsuta, K.; Ishida, M.; et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. *J. Clin. Investig.* **2019**, *130*. [CrossRef] [PubMed]
- 165. Lee, T.F.; Tseng, Y.C.; Chang, W.C.; Chen, Y.C.; Kao, Y.R.; Chou, T.Y.; Ho, C.C.; Wu, C.W. YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas. *Oncotarget* **2017**, *8*, 89539–89551. [CrossRef] [PubMed]
- 166. Lee, T.F.; Tseng, Y.C.; Nguyen, P.A.; Li, Y.C.; Ho, C.C.; Wu, C.W. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. *Sci. Rep.* **2018**, *8*. [CrossRef] [PubMed]
- 167. Xu, W.; Wei, Y.Y.; Wu, S.S.; Wang, Y.; Wang, Z.; Sun, Y.; Cheng, S.Y.; Wu, J.Q. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. *Cell Biosci.* **2015**, 5. [CrossRef]

Cells **2019**, *8*, 600 21 of 22

168. Yamauchi, T.; Moroishi, T. Hippo Pathway in Mammalian Adaptive Immune System. Cells 2019, 8. [CrossRef]

- 169. Zhang, W.Y.; Nandakumar, N.; Shi, Y.H.; Manzano, M.; Smith, A.; Graham, G.; Gupta, S.; Vietsch, E.E.; Laughlin, S.Z.; Wadhwa, M.; et al. Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma. *Sci. Signal.* **2014**, 7. [CrossRef]
- 170. Rozengurt, E.; Sinnett-Smith, J.; Eibl, G. Yes-associated protein (YAP) in pancreatic cancer: At the epicenter of a targetable signaling network associated with patient survival. *Signal. Transduct. Tar.* **2018**, *3*. [CrossRef]
- 171. Kapoor, A.; Yao, W.T.; Ying, H.Q.; Hua, S.J.; Liewen, A.; Wang, Q.Y.; Zhong, Y.; Wu, C.J.; Sadanandam, A.; Hu, B.L.; et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. *Cell* **2014**, 158, 185–197. [CrossRef] [PubMed]
- 172. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. *Nature* **2002**, *417*, 949–954. [CrossRef] [PubMed]
- 173. Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H.; Kaempgen, E.; et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012, 380, 358–365. [CrossRef]
- 174. Fisher, M.L.; Grun, D.; Adhikary, G.; Xu, W.; Eckert, R.L. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. *Oncotarget* 2017, *8*, 110257–110272. [CrossRef] [PubMed]
- 175. Kim, M.H.; Kim, J.; Hong, H.; Lee, S.H.; Lee, J.K.; Jung, E.; Kim, J. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. *EMBO J.* **2016**, *35*, 462–478. [CrossRef] [PubMed]
- 176. Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G.T.; White, S.M.; Weiner, L.M.; Yi, C. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. *Oncogene* **2017**, *36*, 1232–1244. [CrossRef] [PubMed]
- 177. Mohseni, M.; Sun, J.; Lau, A.; Curtis, S.; Goldsmith, J.; Fox, V.L.; Wei, C.; Frazier, M.; Samson, O.; Wong, K.K.; et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. *Nat. Cell Biol.* **2014**, *16*, 108–117. [CrossRef]
- 178. Lee, Y.; Kim, N.H.; Cho, E.S.; Yang, J.H.; Cha, Y.H.; Kang, H.E.; Yun, J.S.; Cho, S.B.; Lee, S.H.; Paclikova, P.; et al. Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. *Nat. Commun.* **2018**, *9*. [CrossRef]
- 179. Zhang, W.J.; Gao, Y.J.; Li, F.M.; Tong, X.Y.; Ren, Y.; Han, X.K.; Yao, S.; Long, F.; Yang, Z.Z.; Fan, H.Y.; et al. YAP Promotes Malignant Progression of Lkb1-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin. *Cancer Res.* **2015**, *75*, 4450–4457. [CrossRef]
- 180. Mo, J.S.; Meng, Z.P.; Kim, Y.C.; Park, H.W.; Hansen, C.G.; Kim, S.; Lim, D.S.; Guan, K.L. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. *Nat. Cell Biol.* **2015**, *17*, 500. [CrossRef]
- 181. DeRan, M.; Yang, J.; Shen, C.H.; Peters, E.C.; Fitamant, J.; Chan, P.; Hsieh, M.; Zhu, S.; Asara, J.M.; Zheng, B.; et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. *Cell Rep.* **2014**, *9*, 495–503. [CrossRef] [PubMed]
- 182. Chen, H.; Liu, H.D.; Qing, G.L. Targeting oncogenic Myc as a strategy for cancer treatment. Signal. Transduct. Tar. 2018, 3. [CrossRef] [PubMed]
- 183. Choi, W.; Kim, J.; Park, J.; Lee, D.H.; Hwang, D.; Kim, J.H.; Ashktorab, H.; Smoot, D.; Kim, S.Y.; Choi, C.; et al. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC. *Cancer Res.* **2018**, *78*, 3306–3320. [CrossRef] [PubMed]
- 184. Chen, X.Y.; Gu, W.T.; Wang, Q.; Fu, X.C.; Wang, Y.; Xu, X.; Wen, Y. C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC. *Oncotarget* 2018, *9*, 668–679. [CrossRef] [PubMed]
- 185. Mamada, H.; Sato, T.; Ota, M.; Sasaki, H. Cell competition in mouse NIH3T3 embryonic fibroblasts is controlled by the activity of Tead family proteins and Myc. *J. Cell Sci.* **2015**, *128*, 790–803. [CrossRef] [PubMed]
- 186. Croci, O.; De Fazio, S.; Biagioni, F.; Donato, E.; Caganova, M.; Curti, L.; Doni, M.; Sberna, S.; Aldeghi, D.; Biancotto, C.; et al. Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. *Gene Dev.* **2017**, *31*, 2017–2022. [CrossRef]
- 187. Elster, D.; Jaenicke, L.A.; Eilers, M.; von Eyss, B. TEAD activity is restrained by MYC and stratifies human breast cancer subtypes. *Cell Cycle* **2016**, *15*, 2551–2556. [CrossRef]

188. Von Eyss, B.; Jaenicke, L.A.; Kortlever, R.M.; Royla, N.; Wiese, K.E.; Letschert, S.; McDuffus, L.A.; Sauer, M.; Rosenwald, A.; Evan, G.I.; et al. A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer. *Cancer Cell* **2015**, *28*, 743–757. [CrossRef]

189. Elster, D.; Tollot, M.; Schlegelmilch, K.; Ori, A.; Rosenwald, A.; Sahai, E.; von Eyss, B. TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells. *Nat. Commun.* **2018**, *9*, 3115. [CrossRef]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).